Testing against Inhalation Anthrax Show Positive Results

The Ernest Orlando Lawrence Berkeley National Laboratory (LBL), Center for Environmental Biotechnology, in Berkeley CA, has performed the initial proof of concept screening of NVC101 against B. anthracis strains and S. pneumoniae cells with positive results

McCLELLAN, Calif., April 29, 2002 - Evit Labs, Inc. and NovaCal Pharmaceuticals, LLC, had previously announced a joint development agreement for the advancement of NVC101 solution, as an inhaled antimicrobial, delivered by the Sonik LDI (sonic liquid dispensing inhaler) for possible use against certain pulmonary infections. Under contract, the Ernest Orlando Lawrence Berkeley National Laboratory (LBL), Center for Environmental Biotechnology, in Berkeley CA, has performed the initial proof of concept screening of NVC101 against B. anthracis strains and S. pneumoniae cells with positive results. Other potential uses of the Sonik LDIÔ with NVC101 for pulmonary applications are being explored through the joint efforts of EVIT and NovaCal.

The Sonik LDI is new technology platform for the sonic aerosolization of liquid pharmaceuticals, anti-bodies, proteins and peptides in a small, non-electrical, portable device.

NVC101 is a proprietary antimicrobial and noncytotoxic solution designed and developed for the prophylaxis and treatment of topical infections in chronic wounds.

About the Companies

NovaCal Pharmaceuticals, LLC is a clinical stage pharmaceutical company committed to the discovery, development and commercialization of patented therapeutic products for the control or elimination of infections. Currently, NovaCal is focused on clinical development and regulatory approval of NVC101 as a unique anti-microbial noncytotoxic product.

Founded in 2000, Evit Labs, Inc is the leader in sonic delivery of high quality, aerosol pharmaceuticals, anti-bodies proteins and peptides through its patented Sonik LDI (liquid dispensing inhaler. The company offers drug and biotech companies a patient friendly, economical, easy formulation, platform in which to deliver treatments to the lungs.

NOTE: Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements and involve risks and uncertainties. They include our reliance on our collaborative partners and our ability to properly design, implement and complete clinical trial; meet regulatory requirements; demonstrate safety and efficacy of products; manage third-party contracts; and avoid infringement of third-party proprietary rights. Actual results may differ materially from those projected. These forward-looking statements represent our best judgment as of the date of the release. We disclaim any intent or obligation to update these forward-looking statements.

Contact Information:
Jack O'Reilly, CEO
NovaCal Pharmaceuticals
415-884-2042 x114
joreilly@novacalpharma.com
or
Jon M. Bergstrom, EVP
Evit Labs, Inc.
916-640-0485
jberg@evitlabs.com